BACKGROUND: The IRIS trial (Insulin Resistance Intervention After Stroke) demonstrated that pioglitazone reduced the risk for both cardiovascular events and diabetes mellitus in insulin-resistant patients. However, concern remains that pioglitazone may increase the risk for heart failure (HF) in susceptible individuals.
I
nsulin resistance is a central feature of type 2 diabetes mellitus, but it is also highly prevalent in patients with cardiovascular disease before the onset of diabetes mellitus. 1, 2 The IRIS trial (Insulin Resistance Intervention After Stroke) demonstrated that pioglitazone, an insulin-sensitizing drug in the thiazolidinedione class, reduced the risk of both cardiovascular events (stroke or myocardial infarction [MI] ) and diabetes mellitus in patients with insulin resistance after a recent stroke or transient ischemic attack. 3 Use of thiazolidinediones has been limited in part by uncertainty about the risk they pose for the development of heart failure (HF). Thiazolidinediones mediate their effects primarily through activation of the peroxisome proliferator-activated receptor γ. The peroxisome proliferator-activated receptor γ is expressed at low levels in the heart, and there are no known deleterious effects of pioglitazone on myocardial metabolism, contractile function, or structure. 4 However, the peroxisome proliferator-activated receptor γ agonists increase sodium reabsorption through the renal epithelial sodium channel, with attendant fluid retention that may lead to HF in susceptible patients. 5 The PROactive trial (Prospective Pioglitazone Clinical Trial in Macrovascular Events) of type 2 diabetes mellitus and macrovascular disease reported a significantly higher rate of hospitalized HF in the pioglitazone group, which was considered to counterbalance some of the benefit of pioglitazone for the prevention of atherosclerotic cardiovascular events. 6, 7 In IRIS, rates of hospitalized and nonhospitalized HF were comparably low in both the pioglitazone and placebo groups. 3 In the current study, we undertook a post hoc secondary analysis of the IRIS trial to identify patients who might be at higher risk for pioglitazone-associated HF to provide additional guidance for a more personalized approach to pioglitazone therapy. We investigated the association among baseline characteristics, postrandomization events (including MI), study drug side effect reports, and dose adjustments on the development of HF in the trial.
METHODS
The data and study materials used in the current study are available to other researchers through the National Institutes of Health/National Institute of Neurological Disorders and Stroke data archive. 8 
Study Participants
IRIS was a double-blind, placebo-controlled randomized clinical trial of pioglitazone for prevention of the composite outcome of stroke or MI conducted at 179 sites in the United States, Canada, Israel, Australia, Germany, Italy, and the United Kingdom. Methods and results have been published previously. 3, 9 Patients were ≥40 years of age, with a qualifying ischemic stroke or transient ischemic attack within the preceding 6 months and insulin resistance (ie, homeostasis model assessment-insulin resistance value >3.0) without diabetes mellitus. Patients who had taken medication for the treatment of diabetes mellitus in the past 90 days or who met diagnostic criteria for diabetes mellitus on the screening blood test (fasting plasma glucose ≥126 mg/dL confirmed by repeat test) or had hemoglobin A1c (HbA1c) ≥7.0% were excluded.
Recognizing the potential for fluid retention and volume expansion on pioglitazone, the study was designed to exclude patients with moderate or severe lower extremity edema or New York Heart Association class III or IV HF. When enrollment started in 2004, patients with class II HF were eligible at US sites if their left ventricular ejection fraction was ≥40%, but this was no longer allowed after guidelines for prescribing pioglitazone were made more stringent in 2007. Beginning in 2008, patients with any history of HF were excluded from enrollment, and the study drug was permanently discontinued in participants who had been enrolled with New York Heart Association class
Clinical Perspective
What Is New?
• In this secondary analysis of the IRIS trial (Insulin Resistance Intervention After Stroke), pioglitazone did not increase the risk of incident heart failure (HF), even in those patients with HF risk factors. • Pioglitazone also reduced the incidence of myocardial infarction, which was a significant postrandomization risk factor for HF.
• The study drug dose could be reduced for symptoms of edema or excessive weight gain.
• Pioglitazone also had a beneficial effect on the overall prespecified composite outcome of fatal and nonfatal stroke and myocardial infarction and hospitalized HF.
What Are the Clinical Implications?
• Insulin resistance is a risk factor for diabetes mellitus and cardiovascular disease.
• IRIS was the first study to show that pioglitazone, a peroxisome proliferator-activated receptor γ agonist with potent insulin-sensitizing and direct vascular protective effects, could reduce both cardiovascular events and diabetes mellitus in insulinresistant patients.
• Pioglitazone has no direct cardiotoxic effects but can cause renal sodium retention, which may lead to HF. • Pioglitazone is no longer used in patients with a history of HF.
• The current findings help provide a more personalized approach to treatment after ischemic stroke or transient ischemic attack of patients who have no history of HF.
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I-II HF. This protocol modification was made because of a concern that these patients would be at increased risk for HF recurrence and subsequent study drug discontinuation, and because of the expansion of recruitment to Europe, where pioglitazone is not used in patients with any history of HF. Because patients with a history of HF are no longer treated clinically with pioglitazone, the cohort for the current study excludes the 25 patients who were enrolled with previous HF (American College of Cardiology stage C patients). The trial was monitored by an independent data and safety monitoring board. All participants gave written informed consent, and the local ethics committee at each participating clinical site approved the protocol before commencement of recruitment.
Intervention and Follow-Up
Study drug dose was initiated at pioglitazone 15 mg daily or matching placebo and, in the absence of contraindications such as significant weight gain, edema, and shortness of breath, was increased to 30 mg at 4 weeks and 45 mg at 8 weeks. During the first 3 months, participants were contacted every 2 weeks; subsequently, participants were contacted every 4 months. Follow-up ended at 5 years or at the last scheduled contact during study closeout in mid-2015, whichever came first.
HF Surveillance and Adjudication
HF (hospitalized and nonhospitalized) was a prespecified safety outcome for the IRIS trial. However, episodes of HF requiring hospitalization ≥24 hours were included as part of the IRIS trial's prespecified secondary outcome of stroke, MI, or hospitalized HF, a composite measure of net cardiovascular treatment effect. The protocol used to track and manage study drug side effects and to identify and adjudicate episodes of HF during the trial is described in detail in the Figures I through III in the online-only Data Supplement. Briefly, at each scheduled contact, patients were asked about new or worsening shortness of breath or edema, excessive weight gain, diagnoses of HF, and all hospitalizations. All HF diagnoses reported or found in hospital records were submitted for adjudication to the external Cardiology Review Committee. Participants who reported new or worse dyspnea or symptomatic leg swelling were required to have an evaluation by the patient's personal healthcare provider or site investigator. If HF was diagnosed locally, then the event was submitted to the Cardiology Review Committee.
Each potential event was adjudicated by 2 cardiologists on the committee who were blinded to treatment assignment, with a third reviewer added if needed to reach consensus. HF was confirmed if findings were present in ≥2 of the following categories: (1) dyspnea in the absence of a noncardiac cause, (2) signs of left HF, and (3) improvement in signs or symptoms in response to diuretic therapy.
Study drug was permanently discontinued if HF was confirmed by the committee. If excessive weight gain, edema, or shortness of breath was reported but HF was not diagnosed, then the study drug could be reduced or discontinued by investigators according to the algorithms. Participants who were off the study drug continued to be followed for all trial outcomes.
Statistical Analysis
Time to first HF event was analyzed by treatment group and in the aggregate (both treatment groups). Cumulative event-free rates were calculated by the Kaplan-Meier methods, 10 and treatment group differences were tested by the log-rank statistic using a type I error of 0.05 (2-sided). The effect of pioglitazone relative to placebo was estimated as a hazard ratio from a Cox model, 11 with 95% CIs. Risk for recurrence was analyzed using the method of Wei, Lin, and Weissfeld. 12 Selected baseline features that are known to be associated with development of HF 13, 14 were examined as predictors of incident HF and as potential modifiers of the effect of pioglitazone on HF. A multivariable Cox model was estimated in the entire study population, with variables selected from the 21 baseline risk features using a stepwise algorithm at a significance level for entry and removal of 0.05 to identify independent risk features. Coefficients from the selected model were rounded to create a risk score, 15 and the effect of pioglitazone on risk for HF was calculated within groups defined by the summary risk score.
In the primary report of IRIS, stroke and MI were defined using 2004 outcome criteria. 9 For the current analysis, updated 2014 American Heart Association/American Stroke Association stroke criteria 16 were used, which define stroke as an acute neurological event with focal signs or symptoms lasting ≥24 hours or a new or extended infarction consistent with the clinical syndrome on brain imaging. Similarly, in the present analysis, MI was defined using the 2012 Third Universal Criteria. 17 Results for the current study were not adjusted for multiplicity. SAS version 9.3 was used for all analyses (SAS Institute Inc).
RESULTS
Twenty-five patients originally enrolled in IRIS had a history of HF. Among these patients, there was a high risk of recurrent HF during the trial (5 of 9 patients on placebo and 7 of 16 patients on pioglitazone). These 25 patients were subsequently taken off the study drug (per a change in protocol) and are excluded from the current study, which focuses on the 3851 patients with no history of HF.
Effect of Pioglitazone on HF by Baseline Risk
Risk factors for HF did not differ at baseline in the pioglitazone and placebo groups (Table I in the online-only Data Supplement). A total of 187 events in 151 patients in the pioglitazone group and 180 events in 144 patients in the placebo group were reported to the external review committee as potential episodes of HF (Table II in the online-only Data Supplement). The 5-year risk of any confirmed HF and nonhospitalized HF did not dif-fer by treatment (Table 1 and Figure 1) . Among the 67 patients on pioglitazone with confirmed HF, 15 died during follow-up (1 from HF). Among the 66 patients on placebo with confirmed HF, 17 died during follow-up (2 from HF). The study drug was permanently stopped in all patients after confirmation of HF. However, recurrent HF occurred in 7 patients on pioglitazone and 9 patients on placebo (Table III in the online-only Data Supplement). The 5-year risk of hospitalized HF was low and not significantly greater in pioglitazone compared to placebo groups (2.9% versus 2.3%, P=0.36). Recurrent hospitalizations for HF were infrequent in both groups (5 of 45 patients in the pioglitazone group and 7 of 37 patients in the placebo group), with no excess risk observed for pioglitazone (Table III in the online-only Data Supplement).
In the aggregate cohort (ie, both treatment groups combined), older age, atrial fibrillation, hypertension history, obesity, preexisting leg edema, and elevated C-reactive protein at baseline were associated with an increased risk for HF during follow-up in univariable and multivariable analyses ( Table 2) . Cigarette smoking was a risk factor after adjustment for age, accounting for the fact that smokers tended to be younger. These patient features were similarly associated with a greater risk for HF when either treatment group was considered separately (Table IV in the online-only Data Supplement). A neutral effect of pioglitazone on HF, including hospitalized HF, was observed consistently across groups defined by individual HF risk factors. When the 7 baseline features that independently predicted HF in the study cohort were combined into a risk score, the effect of treatment was not significant (P=0.93), and the hazard ratios for pioglitazone versus placebo were close to unity across the range of risk (Figure 2 Figure 3A) . HF and MI occurred on the same day for 22 patients (12 in the pioglitazone group and 10 in the placebo group). Among patients with MI, risk for HF (on or after MI) was numerically but not significantly higher in the pioglitazone group compared with the placebo group ( Figure 3B ).
Postrandomization Events and Risk for HF

Myocardial Infarction
Pioglitazone was associated with a significantly lower risk for MI compared with placebo (hazard ratio, 0.69; 95% CI, 0.48-0.99; P=0.04). 18 However, for patients who did have
Study Drug Side Effects
In addition to any reported diagnosis of HF, patients were periodically and carefully assessed for weight gain, lower extremity edema, and shortness of breath during the trial. These complaints were observed in both the pioglitazone and placebo groups, but as previously reported, they were seen more often in those assigned to the active drug. 3 Excessive weight gain was especially common in the pioglitazone group, but it was not related to subsequent development of HF (Table 3) . New or worsened significant lower extremity edema or dyspnea required clinical evaluation for HF by the local investigator or healthcare provider. Patients with these symptoms did have higher rates of confirmed HF in both treatment arms. However, the large majority of patients with edema or dyspnea did not develop HF during the trial (Table 3) .
Study Drug Dose Adjustments
The study drug was permanently withdrawn in all patients confirmed to have HF by the blinded adjudication committee. However, in the absence of HF, investigators could use discretion in stopping the drug or reducing the dose for edema, weight gain, or shortness of breath depending on severity and response to conventional interventions. Among patients without HF during followup, these complaints triggered a reduction in the study drug dose in 7% and discontinuation of the study drug in 13% of the pioglitazone group compared with 3% and 5%, respectively, in the placebo group. In patients without HF, those in the pioglitazone group were less 
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likely to be on the full dose of the study medication throughout the study (Figure 4) . By the trial end, the proportions of these patients who were on a reduced dose or were off the study drug for any reason were 10% and 41% in the pioglitazone group compared with 5% and 35% in the placebo group. The overall mean daily study drug dose during the trial in these patients (with 0 daily dose imputed for periods off the drug) was slightly lower in the pioglitazone group compared to the placebo group (29±17 mg versus 33±15 mg, P<0.0001).
Net Benefit of Pioglitazone on Cardiovascular Risk
To quantify the net cardiovascular benefit of pioglitazone in patients without a history of HF, we assessed the prespecified composite outcome of stroke, MI, or HF Circulation. 
DISCUSSION
Over 5 years, insulin-resistant patients with cerebrovascular disease enrolled in the IRIS trial had a low risk of HF (4.2%), HF hospitalization (2.6%), and HF mortality (<0.1%). Risk for HF did not differ in those assigned to the insulin-sensitizing thiazolidinedione, pioglitazone, a drug previously linked to HF risk in patients with diabetes mellitus. Similar to other cohorts, older age, history of hypertension, atrial fibrillation, leg edema, cigarette smoking, obesity, and elevated C-reactive protein were associated with a greater risk for incident HF in IRIS. However, even among those at higher baseline risk, pioglitazone did not appear to confer additional hazard for HF.
In the PROactive study of 5238 patients with type 2 diabetes mellitus and established macrovascular disease, HF hospitalizations after a mean follow-up of 2.9 years were higher in the pioglitazone arm compared with the placebo group (5.7% versus 4.1%, P=0.007). CRP indicates C-reactive protein; HDL, high-density lipoprotein; HF, heart failure; HOMA-IR, homeostasis model assessment-insulin resistance; and LDL, lowdensity lipoprotein.
*The percentage of participants with HF. †Hazard ratio and P value for baseline feature from univariable Cox model. ‡Hazard ratio and P value for baseline feature from Cox model for features selected by stepwise procedure with P value for entry and retention=0.05.
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A similar trend was observed among the 984 participants with a history of stroke at entry into that trial (6.4% versus 4.0%, P=0.09). 19 Although PROactive excluded patients with New York Heart Association class II-IV HF symptoms, asymptomatic patients with a history of HF were eligible to participate. 16 In comparison with PROactive, IRIS participants had a lower risk for hospitalized HF over 5 years and a smaller increment in risk with treatment (2.9% and 2.3% in the pioglitazone and placebo groups, respectively; absolute risk difference, 0.5%; 95% CI, -0.6 to 1.7). Thus, despite low statistical power, our data argue against a risk increase with treatment >1.7% over 5 years for hospitalized HF.
In both PROactive and IRIS, fatal cases of HF were rare (≤1%) and had a similar incidence in both treatment groups. The low risk for HF observed in our data is consistent with the results of the smaller ACT NOW study (Actos Now for the Prevention of Diabetes), which compared pioglitazone with placebo for the prevention of diabetes mellitus in 602 patients with impaired glucose tolerance. ACT NOW also excluded patients with class II or greater HF symptoms. Only 1 case of HF developed in each treatment group over a median follow-up of 2.4 years. 20 Thus, pioglitazone may pose less of a risk of HF in patients with prediabetes mellitus or insulin-resistant patients without diabetes mellitus than among those with established diabetes mellitus.
The neutral overall effect of pioglitazone on HF in IRIS may have 2 or more additional potential explanations. First, the occurrence of MI during the trial was a strong predictor of coincident or subsequent HF. Because pioglitazone reduced the risk for MI in IRIS, 18 the protection against MI may have helped to neutralize a predisposition to HF that might have otherwise been observed with pioglitazone. Second, the dose of the study drug was titrated slowly over 2 months. The incremental adjustment of pioglitazone from 15 mg to 45 mg daily, in addition to the careful tracking of weight gain, edema, and shortness of breath and study drug dose reductions in response to these complaints, may have helped to lower the risk for HF associated with pioglitazone in this study. Although none of these symptoms was specifically indicative of HF at the time and occurred commonly in both treatment groups, excessive edema and shortness of breath were associated with an increased risk for subsequent HF. Thus, patients with previous stroke or transient ischemic attack who develop either finding should be monitored for development of HF irrespective of the use of pioglitazone.
Limitations of the current analysis warrant consideration. First, it is possible that HF associated with 
pioglitazone might be more evident in clinical practice than in the clinical trial context, particularly in patients who are not as carefully selected for treatment or who do not have the benefit of closer follow-up that is generally provided in a clinical trial. In IRIS, treatment was withdrawn with the onset of HF; in clinical practice, the continuation of therapy or an attempt to treat through early HF with diuretics could conceivably lead to more HF hospitalizations. Of particular concern would be patients with American College of Cardiology stage C or D HF who were not included in our analysis and in whom the risks and benefits of pioglitazone may differ. Second, we did not study how the approach used in IRIS might mitigate cardiovascular risk in patients with established diabetes mellitus, and its efficacy in these patients remains to be determined. Third, similar to previous stroke trials, [21] [22] [23] there was loss to follow-up of some IRIS patients; although the numbers of patients lost were similar in both treatment groups, we cannot exclude the possibility that episodes of HF were differentially missed. However, lost patients had no ongoing access to the study drug, and fluid retention related to pioglitazone therapy was likely not sustained after drug discontinuation because pioglitazone has no known cardiotoxic effects on structure, metabolism, or contractile function. 4 Fourth, these results are not directly generalizable to patients without diabetes mellitus after MI or acute coronary syndromes. Last, the overall benefit of pioglitazone on cardiovascular outcomes needs to be considered in the context of other side effects, including weight gain, edema, and an increased risk of bone fracture. 3 Despite no overall increase in cancer incidence, there has been concern regarding bladder cancer and pioglitazone. A numeric excess on treatment was reported in both HF indicates heart failure. *% of participants who underwent adjudication for HF at any time after symptom was first reported, or at any time during followup if symptom was not reported.
†% of participants with HF confirmed at any time after symptom was first reported, or at any time during follow-up if symptom was not reported.
‡Weight gain over protocol limits of 5 lbs in 4 weeks during first 3 months or 10 lbs over 4 months or 30 lbs from baseline at any time during follow-up.
§Swelling of feet or lower legs that was new or worse since prior interview and that persisted after leg elevation or was associated with pain, discomfort, redness, skin weeping, leakage, breakdown, or more difficulty getting shoes on feet.
‖Shortness of breath that was new or worse since previous interview. 
PROactive 24 and IRIS. 3 However, a recent analysis that combined results from these 2 randomized trials concluded that there was a nonsignificantly increased risk with pioglitazone, 25 which may in part be attributable to detection bias. 26 The present analysis found that pioglitazone had a highly significant net cardiovascular benefit, weighing the protection from stroke and MI along with the risk of HF hospitalization in selected patients who have insulin resistance but neither diabetes mellitus nor a history of HF. A reduction in the dose or discontinuation of pioglitazone in patients who develop excessive weight gain or edema may be appropriate to lessen these symptoms and the risk of HF. These results warrant consideration as clinicians weigh the potential important benefits and the risks of pioglitazone as a secondary prevention therapy after stroke or transient ischemic attack.
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